2022
Evaluation of the Pfs25-IMX313/Matrix-M malaria transmission-blocking candidate vaccine in endemic settings
Mulamba C, Williams C, Kreppel K, Ouedraogo J, Olotu A. Evaluation of the Pfs25-IMX313/Matrix-M malaria transmission-blocking candidate vaccine in endemic settings. Malaria Journal 2022, 21: 159. PMID: 35655174, PMCID: PMC9161629, DOI: 10.1186/s12936-022-04173-y.Peer-Reviewed Original ResearchConceptsEndemic settingsMalaria transmission-blocking vaccineHuman vaccine trialsTransmission-blocking vaccinesPublic health importanceMosquito vectorsMiddle-income settingsAnti-malarial drugsImmunological mechanismsCandidate vaccinesVaccine trialsHealthy individualsIncome settingsTransmission blockingHealth importanceMalaria controlMalaria parasitesVaccineLocal interventionsDrugsInterventionSettingSexual stagesPfs25Disease
2014
Ex vivo anti-malarial drugs sensitivity profile of Plasmodium falciparum field isolates from Burkina Faso five years after the national policy change
Tinto H, Bonkian L, Nana L, Yerbanga I, Lingani M, Kazienga A, Valéa I, Sorgho H, Kpoda H, Guiguemdé T, Ouédraogo J, Mens P, Schallig H, D’Alessandro U. Ex vivo anti-malarial drugs sensitivity profile of Plasmodium falciparum field isolates from Burkina Faso five years after the national policy change. Malaria Journal 2014, 13: 207. PMID: 24885950, PMCID: PMC4049403, DOI: 10.1186/1475-2875-13-207.Peer-Reviewed Original ResearchConceptsP. falciparum sensitivityVivo studiesFirst-line treatmentPlasmodium falciparum fieldAnti-malarial drugsEx vivo studyDrug sensitivity profilesDHA-PPQChloroquine resistanceIC50 valuesPartner drugsDrug efficacy testsDrug measurementsInhibitory concentration valuesMonodesethylamodiaquinePiperaquineEfficacy of ALHigher IC50 valuesPlasmodium falciparumDihydroartemisininFive yearsCellular proliferationDrugsRecent reportsLumefantrine
2007
Amodiaquine Metabolism is Impaired by Common Polymorphisms in CYP2C8: Implications for Malaria Treatment in Africa
Parikh S, Ouedraogo J, Goldstein JA, Rosenthal PJ, Kroetz DL. Amodiaquine Metabolism is Impaired by Common Polymorphisms in CYP2C8: Implications for Malaria Treatment in Africa. Clinical Pharmacology & Therapeutics 2007, 82: 197-203. PMID: 17361129, DOI: 10.1038/sj.clpt.6100122.Peer-Reviewed Original ResearchMeSH KeywordsAlkynesAmodiaquineAntimalarialsAryl Hydrocarbon HydroxylasesBenzoxazinesBurkina FasoChromatography, High Pressure LiquidCyclopropanesCytochrome P-450 CYP2C8Dose-Response Relationship, DrugDrug InteractionsEnzyme InhibitorsGenotypeHIV Protease InhibitorsHumansLopinavirMalaria, FalciparumModels, BiologicalPolymorphism, GeneticPyridinesPyrimidinonesPyronesReverse Transcriptase InhibitorsSaquinavirSpectrophotometry, UltravioletSulfonamidesTreatment OutcomeTrimethoprimConceptsAntimalarial drug amodiaquineMalaria-infected patientsAntiretroviral drug efavirenzImportant clinical implicationsAmodiaquine metabolismCYP2C8 genotypeMalaria treatmentN-desethylamodiaquineCYP2C8 variantsCYP2C8 activityCYP2C8 inhibitorsDrug interactionsDefective metabolismClinical implicationsCYP2C8Common polymorphismsDrug efavirenzMetabolismRelevant concentrationsDrugsEfficacyPrimary metabolitesAllele frequenciesToxicitySample size
2006
In vivo sensitivity of Plasmodium faciparum to chloroquine and sulfadoxine pyrimethamine in the Bobo Dioulasso region (1998-2001): risk factors associated with treatments failures to the two drugs.
Tinto H, Sanou B, Erhart A, D'Alessandro U, Ouédraogo J, Guiguemdé T. In vivo sensitivity of Plasmodium faciparum to chloroquine and sulfadoxine pyrimethamine in the Bobo Dioulasso region (1998-2001): risk factors associated with treatments failures to the two drugs. Bulletin De La Société De Pathologie Exotique 2006, 99: 161-5. PMID: 16983817.Peer-Reviewed Original ResearchConceptsCQ treatment failureTreatment failureRisk factorsMultivariate analysisVivo field testTotal treatment failureYears of ageTime of recruitmentSignificant increaseSulfadoxine-pyrimethamineCQ groupUnivariate analysisHealth centersAge of childrenLate failureLow parasitaemiaBetter efficacyDay 14Therapeutic efficacyDay 0SP groupVivo sensitivityParasitaemiaChloroquineDrugs
2004
Parasitological resistance of Plasmodium falciparum to antimalarial drugs: what physicians should keep in mind.
Tinto H, Ouédraogo J, Traoré M, Guiguemdé T. Parasitological resistance of Plasmodium falciparum to antimalarial drugs: what physicians should keep in mind. Cahiers De Santé 2004, 14: 69-73. PMID: 15454363.Peer-Reviewed Original ResearchConceptsMalaria case managementParasitological resistanceAntimalarial drugsCase managementDrug resistancePlasmodium falciparum drug resistanceSemi-immune subjectsNon-immune subjectsMalaria drug resistanceAttitudes of physiciansSelective drug pressurePublic health practiceTherapeutic decisionsDrug pressureHost immunityParasitological resultsHealth practicesClinical levelPlasmodium falciparumResistant strainsPhysiciansDrugsLower proportionVivoClassification system
2000
The simplified isotopic microtest: a method for studying the drug resistance in vitro of Plasmodium falciparum to antimalarial drugs.
Tinto H, Ouédraogo J, Coulibaly S, Traoré B, Guiguemdé T. The simplified isotopic microtest: a method for studying the drug resistance in vitro of Plasmodium falciparum to antimalarial drugs. Cahiers De Santé 2000, 10: 353-6. PMID: 11125342.Peer-Reviewed Original Research